| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Arcutis Biotherapeutics, Inc. | SVP Chief Financial Officer | Common Stock | 63,607 | $1,621,876 | $25.50 | 02 Feb 2026 | Direct |
| Arcutis Biotherapeutics, Inc. | SVP Chief Financial Officer | Stock Option (right to buy) | 60,000 | 06 May 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| ARQT | Arcutis Biotherapeutics, Inc. | 02 Feb 2026 | 1 | -$33,658 | 4 | SVP Chief Financial Officer | 04 Feb 2026, 19:24 |
| ARQT | Arcutis Biotherapeutics, Inc. | 03 Nov 2025 | 1 | -$2,175 | 4 | SVP Chief Financial Officer | 05 Nov 2025, 18:24 |
| ARQT | Arcutis Biotherapeutics, Inc. | 04 Aug 2025 | 1 | -$1,275 | 4 | SVP Chief Financial Officer | 05 Aug 2025, 18:28 |
| ARQT | Arcutis Biotherapeutics, Inc. | 06 May 2025 | 2 | $0 | 4 | SVP Chief Financial Officer | 07 May 2025, 19:29 |
| ARQT | Arcutis Biotherapeutics, Inc. | 06 May 2025 | 0 | $0 | 3 | SVP Chief Financial Officer | 07 May 2025, 19:27 |